DaVita Inc. (DVA) — ESG & Values Scores

Environment story

DaVita discloses minimal direct environmental metrics. The company reports water conservation (90 million gallons saved across centers in 2025) and acknowledges climate-related risks in filings, but Scope 1, 2, and 3 emissions are not disclosed in available documents. No explicit net-zero target year is stated. The company faces operational water-intensity risks inherent to dialysis provision but does not quantify absolute emissions or publish a dedicated sustainability report with verified GHG accounting. Environmental governance is acknowledged as a Board oversight area, yet the absence of quantified baseline emissions, sectoral reduction targets, and a credible decarbonization roadmap results in a materially reduced score.

Criticisms on file

No quantified Scope 1, 2, or 3 greenhouse gas emissions disclosed in public filings; net-zero target year not stated.
Source: DVA 10-K and Proxy Statement (2025); Community Care Report referenced but full 2025 content not provided in source documents.
Risk disclosure acknowledges ESG goals and disclosures as a material risk factor but provides no baseline emissions inventory or credible decarbonization pathway.
Source: DVA 10-K Item 1A Risk Factors and MD&A forward-looking statements section.

Disclosed initiatives

Water Conservation Across Dialysis Centers

DaVita reports saving more than 90 million gallons of water through ongoing conservation efforts across its dialysis center network in 2025.

Localized resource efficiency; does not quantify absolute water consumption baseline or Scope 1/2/3 emissions reductions.
Environmental, Social and Governance Governance Structure

Nominating and Governance Committee reviews the Company's activities, policies and programs related to environmental, sustainability and governance matters, including corporate environmental and social responsibility, and their impact on the Company, teammates and communities.

Governance acknowledgment of ESG oversight; no specific emissions reduction or renewable energy targets disclosed.

Social story

DaVita operates a labor-intensive business with acknowledged workforce challenges: nationwide nursing shortages, elevated turnover pressures, and active union organizing campaigns in California clinics. The company reports 78,000+ teammates globally and a 2025 employee engagement score of 85%, investments in clinical advancement programs (Clinical Ladders, Bridge to Your Dreams nursing education), and paid volunteer commitments. However, CEO-to-median-worker pay ratio is not disclosed in available documents. Union activity is ongoing: union petitions filed at multiple California clinics, one week-long attempted work stoppage (which did not disrupt patient care), and targeted corporate campaigns by union organizers requiring substantial company resources. Diversity metrics for executive and board leadership are partially disclosed (8 of 9 board members identified by gender; racial/ethnic diversity shown in governance matrix). No formal modern slavery statement, living wage commitment, or supply-chain human rights audit is evident in filings.

Criticisms on file

Active union organizing campaigns at California dialysis clinics; union petitions filed at multiple facilities; company won some elections but subject to legal challenges and ongoing voting processes.
Source: DVA 10-K Item 1A Risk Factors — 'If union organizing or other activities...result in significant increases in our operating costs...'
Week-long attempted union-related work stoppage at some California clinics; union organizers conducting targeted corporate campaigns requiring substantial company resource expenditure.
Source: DVA 10-K Item 1A Risk Factors and Risk Summary.
Nationwide shortage of skilled clinical personnel (nurses, nurse practitioners) and elevated labor costs; company faces increased compensation levels and difficulty hiring and retaining clinical staff.
Source: DVA 10-K Item 1A Risk Factors — 'Our business is labor intensive...'
CEO-to-median-worker pay ratio not disclosed in available filings; transparency gap on executive compensation relative to frontline workforce.
Source: DVA Proxy Statement (2025); pay ratio disclosure section not explicitly provided in source documents.

Disclosed initiatives

Clinical Ladders Program

Clear pathways for career advancement in clinical roles; investment in employee development and retention.

Addresses nursing shortage and skill-development needs; retention benefit in competitive labor market.
Bridge to Your Dreams Nursing Education

DaVita-funded Associate Degree in Nursing program; 400+ teammates pursuing degrees as of 2025.

Mitigates acute nursing shortage; builds internal clinical workforce pipeline.
Community Volunteerism and Health Outreach

70,000+ volunteer hours in 2025; cumulative 218,000+ hours since 2021. Partnerships with YMCA, American Kidney Fund, and American Diabetes Association for chronic disease screening and kidney disease prevention (757,000+ individuals reached in 2025).

Community health impact; employee engagement and social responsibility; brand reputation alignment with patient care mission.
Employee Engagement Programs

2025 employee engagement survey reached five-year high of 85%; ongoing communication and workplace culture initiatives.

Workforce retention and morale; reduces turnover and associated training costs.

Governance story

DaVita exhibits strong governance structural elements: 8 of 9 board members (89%) are independent under NYSE standards; single-class common stock structure (no dual-class voting); annual director elections with majority-vote standard in uncontested elections; robust board oversight committees (Audit, Compensation, Compliance & Quality, Nominating & Governance); 96% average director attendance at meetings in 2025; active stockholder engagement (59% of outstanding shares engaged since 2025 annual meeting); independent Board Chair (Pamela Arway since June 2020); proxy access for shareholders holding 3% for 3 years; no poison pill; robust code of conduct and ethics. However, governance deductions apply: board independence slightly below 90% threshold (8 of 9 = 89%, vs. common 100% or near-100% targets); lobbying expenditures and PAC contributions are overseen but specific annual spending amounts not disclosed in available filings; the company faces ongoing antitrust and regulatory scrutiny related to health insurance network adequacy (Marietta v. DaVita Supreme Court decision), state legislative initiatives targeting dialysis provider reimbursement, and multiple pending litigation matters and government investigations.

Criticisms on file

Supreme Court decision in Marietta Memorial Hospital Employee Health Benefit Plan v. DaVita Inc. regarding network adequacy and ESRD benefit discrimination; ongoing uncertainty regarding payors' ability to restrict access to or limit reimbursement for ESRD treatments; proposed and pending legislative responses.
Source: DVA 10-K Item 1A Risk Factors — 'If the number or percentage of patients with higher-paying commercial insurance declines...'
Multiple state legislative initiatives to limit payments to dialysis providers, impose operational requirements, or prescribe wage levels; company faces costs to oppose such initiatives; if passed, could materially reduce revenues and increase operating costs.
Source: DVA 10-K Item 1A Risk Factors — 'Our business is subject to a complex set of governmental laws...'
Company subject to ongoing governmental investigations, audits, and legal proceedings; pending litigation and qui tam complaints; specific pending matters referenced in Note 15 to consolidated financial statements (details not provided in source documents).
Source: DVA 10-K Item 1A Risk Factors — 'We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations...'
April 2025 cybersecurity incident affecting billing systems and patient care operations; company activated contingency plans and provided continued care across 3,000+ dialysis centers; incident required management attention and operational mitigation.
Source: DVA Proxy Statement (2026 Letter to Stockholders) and MD&A forward-looking statements.
Antitrust and regulatory scrutiny related to acquisitions, mergers, and competitive activities; potential state pre-merger notification and approval requirements could impact transaction ability or timing.
Source: DVA 10-K Item 1A Risk Factors — 'We may engage in acquisitions, mergers, joint ventures...'
Lobbying expenditures and PAC contributions amounts not quantified in available filings; policy oversight disclosed but specific annual spending not reported.
Source: DVA Proxy Statement governance disclosures; annual lobbying and PAC spending figures not explicitly provided.

Disclosed initiatives

Independent Board Chair Leadership

Pamela M. Arway, an independent director (Board member since May 2009), has served as independent Board Chair since June 2020. Chair serves as liaison between management and independent directors, presides over executive sessions, and oversees board evaluations.

Separation of CEO and Board Chair roles enhances independent oversight; reduces agency risk.
Robust Board and Committee Oversight Structure

Four standing Board committees with independent chairs: Audit Committee (Jason Hollar), Compensation Committee (Barbara Desoer), Compliance & Quality Committee (Gregory Moore), Nominating & Governance Committee (Pamela Arway). All committee members are independent. Committees have authority to retain independent advisors. 27 Board and Committee meetings held in 2025.

Distributed oversight of audit, compensation, regulatory compliance, and governance; reduces concentration of decision-making authority.
Annual Board Self-Evaluation and Refreshment

Annual evaluation process includes written questionnaires and rotating live interviews with each director (every other year); individual director evaluations; Board Chair one-on-one discussions; follow-up actions documented and reported. Nominating & Governance Committee considers effectiveness of evaluation process annually.

Continuous Board performance improvement; identification of skill gaps and succession planning; transparency in director assessment.
Stockholder Engagement and Proxy Access

Year-round stockholder engagement; 59% of outstanding shares engaged since 2025 annual meeting. Proxy access allows shareholders (or groups) holding 3% for 3 years to nominate up to the greater of 2 or 20% of directors. Majority-vote standard for director elections (uncontested). Stockholders may call special meetings at 10% ownership threshold. No poison pill.

Enhanced shareholder voice in governance; reduced entrenchment risk; alignment of board with investor interests.
Political and Lobbying Expenditure Oversight

Nominating & Governance Committee oversees the Company's Policy Regarding Political and Lobbying Expenditures, including review of corporate political contributions, lobbying activities, and trade association payments. Committee regularly monitors risks related to political activities and PAC contributions.

Governance transparency and accountability for political spending; reduces reputational risk from misaligned advocacy.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of DaVita Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open DaVita Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)